JP2023513700A5 - - Google Patents
Info
- Publication number
- JP2023513700A5 JP2023513700A5 JP2022548459A JP2022548459A JP2023513700A5 JP 2023513700 A5 JP2023513700 A5 JP 2023513700A5 JP 2022548459 A JP2022548459 A JP 2022548459A JP 2022548459 A JP2022548459 A JP 2022548459A JP 2023513700 A5 JP2023513700 A5 JP 2023513700A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation according
- patient
- formulation
- migalastat
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972392P | 2020-02-10 | 2020-02-10 | |
| US62/972,392 | 2020-02-10 | ||
| PCT/US2021/017446 WO2021163183A1 (en) | 2020-02-10 | 2021-02-10 | Methods of treating fabry disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513700A JP2023513700A (ja) | 2023-04-03 |
| JP2023513700A5 true JP2023513700A5 (https=) | 2024-02-21 |
Family
ID=77272302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548459A Pending JP2023513700A (ja) | 2020-02-10 | 2021-02-10 | ファブリー病の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210251972A1 (https=) |
| EP (2) | EP4732901A2 (https=) |
| JP (1) | JP2023513700A (https=) |
| KR (1) | KR20220150902A (https=) |
| AU (1) | AU2021218578A1 (https=) |
| CA (1) | CA3167476A1 (https=) |
| DK (1) | DK4103178T3 (https=) |
| FI (1) | FI4103178T3 (https=) |
| LT (1) | LT4103178T (https=) |
| PT (1) | PT4103178T (https=) |
| WO (1) | WO2021163183A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US12594268B2 (en) * | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
-
2021
- 2021-02-10 KR KR1020227030895A patent/KR20220150902A/ko active Pending
- 2021-02-10 WO PCT/US2021/017446 patent/WO2021163183A1/en not_active Ceased
- 2021-02-10 LT LTEPPCT/US2021/017446T patent/LT4103178T/lt unknown
- 2021-02-10 JP JP2022548459A patent/JP2023513700A/ja active Pending
- 2021-02-10 DK DK21753606.9T patent/DK4103178T3/da active
- 2021-02-10 PT PT217536069T patent/PT4103178T/pt unknown
- 2021-02-10 CA CA3167476A patent/CA3167476A1/en active Pending
- 2021-02-10 AU AU2021218578A patent/AU2021218578A1/en active Pending
- 2021-02-10 US US17/172,846 patent/US20210251972A1/en active Pending
- 2021-02-10 EP EP25226333.0A patent/EP4732901A2/en active Pending
- 2021-02-10 FI FIEP21753606.9T patent/FI4103178T3/fi active
- 2021-02-10 EP EP21753606.9A patent/EP4103178B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513700A5 (https=) | ||
| López-Bescós et al. | Long-term safety and efficacy of ivabradine in patients with chronic stable angina. | |
| JP3776931B2 (ja) | Ａｃｅ阻害剤ラミプリルとジヒドロピリジン化合物を含有する新規医薬組成物 | |
| FI4103178T3 (fi) | Menetelmiä fabryn taudin hoitamiseksi | |
| ES2150889T3 (es) | Combinacion de glibenclamida-metformina para el tratamiento de la diabetes mellitus tipo ii. | |
| US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| WO2008002514A2 (en) | Combination cough treatment compounds and method of treating common coughs | |
| JP2020531550A5 (https=) | ||
| JP2021512896A5 (https=) | ||
| JP2024178420A5 (https=) | ||
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| Abdollah et al. | Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| US20050256131A1 (en) | Pharmaceutical active substance combination and the use thereof | |
| GB2181053A (en) | Controlled release formulation | |
| Levy et al. | Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing | |
| JP2024525760A5 (https=) | ||
| McHugh et al. | Propafenone ingestion | |
| CN102065856A (zh) | 决奈达隆与至少一种利尿药的组合及其治疗用途 | |
| Uusitalo | Long Term Efficacy of a Controlled-Release Formulation of Isosorbide 5-Mononitrate (Imdur®) in Angina Patients Receivingβ-Blockers | |
| Afzal et al. | Unique case of cardiogenic shock in the setting of cumulative calcium channel blocker toxicity | |
| Fiddes et al. | Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension | |
| RU2358732C2 (ru) | Жидкие фармацевтические композиции, содержащие производные 3,7-диазабицикло(3,3,1)нонана, для лечения антиаритмических реакций | |
| CN101564394A (zh) | 含有伊伐布雷定和曲美他嗪的药物组合物 | |
| Arnman et al. | Plasma concentration of disopyramide given as capsules and controlled release tablets |